Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma

Author:

Chari Ajai1,Suvannasankha Attaya2,Fay Joseph W.3,Arnulf Bertrand4,Kaufman Jonathan L.5,Ifthikharuddin Jainulabdeen J.6,Weiss Brendan M.7,Krishnan Amrita8,Lentzsch Suzanne9,Comenzo Raymond10,Wang Jianping11,Nottage Kerri11,Chiu Christopher12,Khokhar Nushmia Z.12,Ahmadi Tahamtan12,Lonial Sagar5

Affiliation:

1. Tisch Cancer Institute, Mount Sinai School of Medicine, New York, NY;

2. Indiana University School of Medicine and Simon Cancer Center, Richard L. Roudebush VA Medical Center, Indianapolis, IN;

3. Baylor Institute for Immunology Research, Dallas, TX;

4. Unité d’Immuno-hématologie, Assistance Publique–Hôpitaux de Paris, Centre d’Investigations Cliniques 1427, Hôpital Saint Louis Lariboisière, Paris, France;

5. Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA;

6. James P. Wilmot Cancer Center, University of Rochester Strong Memorial Hospital, Rochester, NY;

7. Abramson Cancer Center and Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA;

8. The Judy and Bernard Briskin Myeloma Center, City of Hope, Duarte, CA;

9. Columbia University Medical Center, New York, NY;

10. Division of Hematology-Oncology, Tufts Medical Center, Boston, MA;

11. Janssen Research & Development, Raritan, NJ; and

12. Janssen Research & Development, Spring House, PA

Abstract

Key PointsNo new safety signals were observed with daratumumab plus pomalidomide and dexamethasone, except for increased neutropenia. Daratumumab plus pomalidomide and dexamethasone induced rapid, deep, and durable responses in heavily treated patients with multiple myeloma.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Reference29 articles.

1. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter International Myeloma Working Group study;Kumar;Leukemia,2012

2. Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma;Usmani;Blood,2016

3. The Myeloma Beacon. Darzalex approved in Europe. Available at: http://www.myelomabeacon.com/news/2016/05/24/darzalex-daratumumab-europe-approval/. Accessed 12 May 2017.

4. The Myeloma Beacon. Darzalex (daratumumab) approved by Health Canada as the first human anti-CD38 monoclonal antibody for the treatment of multiple myeloma. Available at: http://www.myelomabeacon.com/pr/2016/06/30/darzalex-approved-by-health-canada/. Accessed 12 May 2017.

5. US Food and Drug Administration. FDA approves Darzalex for patients with previously treated multiple myeloma [press release]. Available at: https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm472875.htm. Accessed 12 May 2017.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3